Oxford/AZ Vaccine Hits 70% Efficacy In Phase III Trials

90% Response Seen In Half Dose Trial

Topline results have produced a lower efficacy rate than seen in the Pfizer and Moderna trials, but a subgroup receiving a half-dose in their first injection showed a 90% efficacy result.  

Coronavirus Covid-19 Protection and Vaccine. Medical hand glove blue molding vial vaccine hypodermic needle syringe injection treatment.
The positive interim results are the third in three weeks, following on from Pfizer and Moderna.

The COVID-19 vaccine being developed by Oxford University and AstraZeneca has achieved 70% efficacy in the first Phase III interim analysis – with an "intriguing" signal which suggests a lower first dose could boost this result to 90%.

The results are the third positive readout from a COVID-19 vaccine trial in as many weeks, following the 90% plus...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from COVID-19

More from Scrip